← Back to Search

Immunoglobulin Replacement Therapy

Panzyga for Chronic Lymphocytic Leukemia

Phase 3
Waitlist Available
Research Sponsored by Octapharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥18 years of age.
Treatment-naïve or relapsed/refractory CLL patients undergoing CLL antineoplastic treatment. Diagnosis of B-cell CLL established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and documented within medical records.
Must not have
Severe liver disease, with signs of ascites and/or hepatic encephalopathy.
Planned or ongoing immunosuppressive treatment (other than for CLL or corticosteroids) or other forbidden medication during the entire study duration after study enrollment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights
Pivotal Trial

Summary

This trial is testing Panzyga, a medication made from human blood plasma, to see if it can help prevent infections in patients with Chronic Lymphocytic Leukemia. These patients have weakened immune systems and need extra antibodies to fight off infections. Panzyga is used to prevent serious bacterial infections.

Who is the study for?
This trial is for adults over 18 with Chronic Lymphocytic Leukemia (CLL) who have low IgG levels and are either untreated or relapsed. They must not have had major infections recently, severe liver or kidney disease, weigh over 140 kg, or be HIV positive. Women of childbearing age must agree to use contraception.
What is being tested?
The study tests Panzyga's effectiveness in preventing infections in CLL patients compared to a placebo. It's double-blind meaning neither the participants nor the researchers know who gets what treatment until after the results are analyzed.
What are the potential side effects?
Possible side effects include allergic reactions like anaphylaxis, systemic responses to immunoglobulin or blood products, and potential increased risk of blood clots due to hypercoagulable states.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have CLL and am starting or retrying treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have severe liver disease with symptoms like fluid in the abdomen or confusion.
Select...
I am not on any immunosuppressive drugs or forbidden medications for the study.
Select...
I have a condition or cancer other than CLL that may shorten my life to under two years.
Select...
I have tested positive for HIV.
Select...
My daily activity is significantly limited due to my health.
Select...
I do not have an active hepatitis C infection.
Select...
I have had a clotting event like a stroke or deep vein thrombosis in the past 6 months.
Select...
I have not received IgG treatment in the last 3 months.
Select...
I have chronic hepatitis B but won't get antiviral therapy during my CLL treatment.
Select...
My kidney function is severely impaired.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Occurrence of major infections
Secondary study objectives
Duration of prophylaxis with anti-infectives
Frequency of prophylaxis with anti-infectives
Overall infection rate

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PanzygaExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panzyga
2011
Completed Phase 3
~420

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Chronic Lymphocytic Leukemia (CLL) include Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib), which block signals that promote the survival and proliferation of CLL cells; BCL2 inhibitors (e.g., venetoclax), which induce apoptosis in CLL cells by inhibiting the BCL2 protein; and monoclonal antibodies (e.g., rituximab), which target specific antigens on CLL cells to mark them for destruction by the immune system. Intravenous immunoglobulin (IVIG), such as Panzyga, provides a broad spectrum of antibodies that can enhance the immune response and reduce the risk of infections, which is particularly important for CLL patients who are often immunocompromised. These treatments are crucial as they not only target the cancer cells but also help manage the immune deficiencies associated with CLL, improving patient outcomes and quality of life.

Find a Location

Who is running the clinical trial?

OctapharmaLead Sponsor
85 Previous Clinical Trials
11,010 Total Patients Enrolled
~38 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top